Trials / Unknown
UnknownNCT05990517
Autologous Transplantation of Expanded Pancreatic Islet Cells (YD01-2022) in Patients
Evaluation of the Efficacy and Safety of Autologous Transplantation of Expanded Pancreatic Islet Cells (YD01-2022) in Patients With Diabetes Mellitus After Total Pancreatectomy
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 3 (estimated)
- Sponsor
- Shanghai Jiao Tong University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of autologous transplantation of expanded pancreatic islet cells in patients with diabetes mellitus after total pancreatectomy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | YD01-2022 | Human islet cells were isolated and expanded in vitro to generate islets containing all types of pancreatic endocrine cells and possessing comparable function of human islets. These islet cells will be infused into the hepatic portal vein. |
Timeline
- Start date
- 2023-02-22
- Primary completion
- 2024-08-01
- Completion
- 2025-08-01
- First posted
- 2023-08-14
- Last updated
- 2023-08-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05990517. Inclusion in this directory is not an endorsement.